Loading data for UPB — first visit, this takes a few seconds.

Alerta

Upstream Bio Inc. (UPB)

NasdaqGS: UPB · Precio en tiempo real · USD

6.97

+0.12 (1.75%)

Al cierre: Aug 21, 2026, 3:59 PM

6.84

-1.87%

Fuera de horario: 7:30 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

1.75% (1D)

Precio de compra	4.94
Capitalización de mercado	381.75M
Ingresos (TTM)	3.16M
Beneficio neto (TTM)	-156.5M
	n/a
	-2.93
	n/a
	-2.38
P/B (TTM)	1.25
P/S (TTM)	120.88
Fecha de resultados	Nov 4, 2026

Precio de venta	8.85
Volumen	434,117
Volumen medio (20D)	607,950
Abierto	6.91
Anterior Cerrar	6.85
Rango del día	6.85 - 7.01
Rango de 52 semanas	5.85 - 33.68
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de UPB

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headqu...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Oct 11, 2024

Empleados 75

Bolsa de Valores NasdaqGS

Símbolo bursátil UPB

Sitio web https://upstreambio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Upstream Bio fueron 2.85M, un aumento de 20.42% en comparación con 2.37M del año anterior. Las ganancias fueron -143.44M, un aumento de 128.39%.

Estados financieros

Sorpresa de resultados

Upstream Bio ha publicado sus resultados trimestrales en Aug 11, 2026:

Ingresos de $1.03M falla las estimaciones por $0, con 82.69% Crecimiento interanual.
EPS de -0.73 supera las estimaciones en 0.03, con 1.35% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Upstream Bio Inc. publique sus resultados el Nov 4, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 mes hace · Zacks

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 mes hace · Insider Monkey

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc. (NASDAQ:UPB) is one of the most promising stocks on our list. TheFly reported ...

1 mes hace · Insider Monkey

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, ...

3 meses hace · Zacks

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Página 1 de 2

Upstream Bio Inc. (UPB)